Tumors shrink when their cells are killed faster than they can divide, and modern oncology has developed a surprisingly wide toolkit for accomplishing that. Chemotherapy, radiation, surgery, immunotherapy, targeted drugs, and hormone therapy each attack tumors through different mechanisms, and they are frequently combined. The variety matters because no single approach works against every cancer, and what shrinks one person’s tumor may barely dent another’s, even when the diagnosis is the same on paper.
Chemotherapy and Radiation, the Two Workhorses
Chemotherapy drugs shrink tumors primarily by damaging the DNA inside cancer cells. Because cancer cells divide rapidly, they are especially vulnerable to agents that interfere with DNA replication. When cells detect that damage, they attempt to repair it, but if the damage is severe enough, they stall and die.1PubMed Central. Chemotherapy induced DNA damage response: convergence of drugs and pathways Different chemotherapy drugs achieve this through different routes: some directly break DNA strands, others block the enzymes that unwind DNA during copying, and still others masquerade as DNA building blocks so the replication machinery jams. The common thread is forcing the cell into a crisis it cannot recover from.
Radiation therapy works on a similar principle but delivers the damage from outside the body using high-energy beams. The most lethal form of radiation-induced damage is the double-strand break, where both rails of the DNA ladder snap at nearly the same spot.2PubMed Central. Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response Cells have repair machinery for single-strand breaks, but double-strand breaks are far harder to fix correctly, and when the repair fails, the cell dies or stops dividing.3PubMed Central. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy Modern radiation techniques shape the beam to focus on the tumor while sparing as much surrounding tissue as possible, but the underlying kill mechanism has not changed much since radiation was first used against cancer.
An intriguing twist with radiation is the abscopal effect, where irradiating a tumor in one part of the body occasionally causes unirradiated tumors elsewhere to shrink too. This appears to happen because radiation-killed cells release debris that alerts the immune system, prompting immune cells to hunt down cancer elsewhere.4PubMed. The abscopal effect of radiation therapy The abscopal effect is uncommon on its own, but researchers are actively trying to make it more reliable by combining radiation with immunotherapy drugs.
Surgery and Tumor Debulking
Surgical removal is the most direct way to eliminate a tumor. When a cancer is caught early and confined to one area, a surgeon can often cut out the entire mass along with a margin of healthy tissue. For more advanced cancers, particularly ovarian cancer, surgeons perform what is called debulking, removing as much visible tumor as possible even if complete removal is not achievable. The logic is that leaving fewer cancer cells behind gives chemotherapy a better shot at finishing the job. In ovarian cancer specifically, optimal debulking removes roughly ninety percent of the tumor mass, while a single course of chemotherapy can destroy a far higher proportion of the remaining cells.5PubMed Central. Surgical Debulking of Ovarian Cancer: What Difference Does It Make? That partnership between the scalpel and the drugs is why surgery and chemotherapy are so often paired.
Targeted Therapies
Where chemotherapy damages any rapidly dividing cell, targeted therapies aim at specific molecules that cancer cells depend on. Tyrosine kinase inhibitors, for example, block signaling proteins that tell cells to grow and multiply. By jamming those signals, targeted drugs can trigger cancer cells to self-destruct while mostly leaving healthy cells alone.6PubMed Central. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies The improvement can be dramatic. In chronic myeloid leukemia, eight-year survival rose from under fifteen percent before 1983 to about eighty-seven percent after the introduction of imatinib, one of the first targeted drugs, in 2001.6PubMed Central. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
The catch is that targeted therapies only work when the tumor carries the specific molecular target they are designed for. A lung cancer patient whose tumor has a particular mutation in the EGFR gene may respond beautifully to an EGFR-targeting drug, while a patient whose lung cancer lacks that mutation will see no benefit. This is why oncologists increasingly order genetic profiling of tumors before choosing treatment.
Immunotherapy
Cancer cells often survive by hiding from the immune system. They exploit built-in brakes on immune cells, called checkpoints, that normally prevent the immune system from attacking the body’s own tissues. Checkpoint inhibitor drugs release those brakes, allowing immune cells to recognize and kill tumor cells. Drugs targeting the PD-1/PD-L1 and CTLA-4 checkpoints have been used successfully in metastatic melanoma, kidney cancer, head and neck cancers, and non-small cell lung cancer, among others.7PubMed Central. Immune Checkpoint Inhibitors in Cancer Therapy Newer checkpoint targets, including LAG-3, TIM-3, and TIGIT, are in various stages of clinical development, aiming to help patients whose tumors do not respond to the first-generation drugs.8PubMed. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
Immunotherapy’s greatest strength is that it can produce responses that last years, because the immune system can remember and continue to patrol for cancer cells long after treatment ends. Its greatest weakness is that it works well in only a fraction of patients, and predicting who will benefit remains an active area of research.
Hormone Therapy
Some cancers, particularly breast and prostate cancers, rely on hormones like estrogen or testosterone to fuel their growth. Hormone therapy shrinks these tumors by cutting off that fuel supply, either by blocking the hormone from reaching cancer cells or by lowering the body’s production of the hormone altogether. This approach can be used before surgery to reduce tumor size, after surgery to prevent recurrence, or as a primary treatment for advanced disease.9Medicine. Systemic therapy Hormonal therapy for cancer In prostate cancer, androgen deprivation therapy alone produced a roughly fivefold increase in cancer cell death in animal models, and combining it with a second agent pushed that to a tenfold increase.10PubMed Central. Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo
Hormone therapy tends to be well-tolerated compared with chemotherapy, but it is effective only in hormone-sensitive cancers. When tumors lose their hormone receptors, or when they find alternative growth signals that bypass the hormonal pathway, hormone therapy stops working.
Starving the Blood Supply
Tumors cannot grow beyond a few millimeters without building their own blood supply, a process called angiogenesis. Anti-angiogenic drugs block the signals that tumors send to recruit new blood vessels, most commonly by targeting a molecule called VEGF.11PubMed Central. Beyond starving cancer: anti-angiogenic therapy Without fresh blood vessels delivering oxygen and nutrients, the tumor’s growth slows and can reverse. These drugs are rarely used alone. They are more commonly combined with chemotherapy or immunotherapy, where choking off blood supply and directly killing cells work in tandem. One practical benefit of anti-angiogenic drugs is that by “normalizing” the chaotic blood vessels inside tumors, they can actually improve the delivery of chemotherapy drugs to the tumor interior, making the combination more effective than either approach alone.
How Doctors Measure Whether a Tumor Is Shrinking
Measuring tumor shrinkage is less straightforward than it sounds. The standard approach, known as RECIST, uses CT or MRI scans to track changes in tumor diameter over time. A tumor that shrinks by at least thirty percent in its longest dimension is classified as a partial response. Complete disappearance on imaging counts as a complete response. However, size alone does not always tell the full story: a tumor can be the same size but metabolically dead inside. That limitation led to the development of PET-based criteria (called PERCIST) that measure metabolic activity rather than just physical dimensions.12Journal of Nuclear Medicine. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
An even faster readout may come from blood tests. In one study of lung cancer patients on immunotherapy, circulating tumor DNA in the blood showed a treatment response a median of about six weeks earlier than imaging did.13Clinical Cancer Research. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA This kind of early signal could help doctors know sooner whether a treatment is working and switch strategies faster when it is not.
When Tumors Appear to Grow Before Shrinking
Immunotherapy has introduced a confusing pattern called pseudoprogression, in which a tumor appears to get larger on scans before eventually shrinking. This happens because the immune cells flooding into the tumor make it swell temporarily, even as they are actively killing cancer cells inside. The danger is that a doctor might see the growth on a scan and stop a treatment that is actually working.14PubMed Central. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy Pseudoprogression is not the norm; it occurs in a minority of patients. But it has forced oncologists to develop new response criteria that allow for an initial increase in tumor size before calling a treatment a failure. The challenge is distinguishing pseudoprogression from genuine worsening, and tools like circulating tumor DNA and serial metabolic imaging are being explored to help make that call.
Why Tumors Fight Back
Even when a treatment initially shrinks a tumor, cancer cells can evolve resistance. This is the single biggest obstacle in cancer therapy. In targeted therapy, the most common resistance mechanism involves the tumor developing new mutations that change the shape of the target protein, so the drug no longer fits.15PubMed Central. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy But tumors have other tricks too. They can activate backup signaling pathways that bypass the blocked one entirely, or they can undergo phenotypic shifts that change their cell type. Some resistance appears to emerge from a small subpopulation of cells that survive the initial treatment, lying low and eventually regrowing as the dominant population in a drug-resistant tumor.15PubMed Central. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
The physical structure of tumors contributes to resistance as well. Solid tumors are not just clusters of cancer cells; they are surrounded by a dense scaffold of proteins and other structural molecules that can block drugs from penetrating to the tumor’s core.16PubMed Central. Towards extracellular matrix normalization for improved treatment of solid tumors Cells in the interior of a large tumor may never see a therapeutic dose of a drug, even when the outer layers are being destroyed. Research into normalizing the tumor’s structural scaffold is underway as a strategy to improve drug penetration.
Oncolytic Viruses
One of the more inventive approaches to tumor shrinkage uses viruses that have been engineered or selected to infect and kill cancer cells while sparing normal tissue. These oncolytic viruses replicate inside tumor cells, burst them open, and then spread to neighboring cancer cells. The cell debris they release also alerts the immune system, creating a secondary wave of tumor killing.17PubMed Central. Oncolytic virus therapy: A new era of cancer treatment at dawn Tumor selectivity comes partly from the fact that cancer cells often have defective antiviral defenses, and partly from engineering the viruses to enter cells through receptors that are unusually abundant on tumor surfaces.18JAMA Oncology. Oncolytic Viruses in Cancer Treatment: A Review A modified herpes virus called talimogene laherparepvec (T-VEC) became the first oncolytic virus approved by the FDA, used for advanced melanoma by direct injection into tumors. The field is still young, and most oncolytic viruses are in clinical trials rather than routine use, but the dual-action mechanism of direct cell killing plus immune activation is compelling.
Nanoparticle Drug Delivery
Getting enough drug into the tumor while limiting damage to the rest of the body is a persistent challenge. Nanoparticle-based delivery systems aim to improve this by packaging drugs into tiny carriers that accumulate preferentially in tumors. Tumors tend to have leaky blood vessels and poor drainage, so nanoparticles that would normally be cleared from healthy tissue can build up in the tumor. Compared to conventional drugs, nanoparticle formulations offer improved stability, better penetration into tumor tissue, and the ability to target specific cells.19PubMed Central. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance Nanoparticles can also help overcome drug resistance by bypassing the molecular pumps that cancer cells use to eject chemotherapy drugs. Several nanoparticle-based cancer drugs are already approved and in clinical use, with more in development.
Fasting-Mimicking Diets as an Adjunct
A growing body of research is exploring whether dietary interventions can make standard cancer treatments more effective. Fasting-mimicking diets, which are severely calorie-restricted regimens lasting several days around each treatment cycle, appear to stress cancer cells in ways that healthy cells can tolerate but cancer cells cannot. Preclinical work in animals has been encouraging, and early clinical trials have begun to produce results.20PubMed Central. Fasting and fasting-mimicking diets for chemotherapy augmentation In a phase 2 trial of thirty patients with early-stage triple-negative breast cancer, combining a fasting-mimicking diet with standard chemotherapy before surgery produced strong rates of complete pathologic response and favorable long-term outcomes.21PubMed. Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients
The biology is nuanced. In colorectal cancer models, fasting slowed tumor growth but did not actually make chemotherapy better at killing cancer cells through the usual pathways. Instead, fasting pushed some cancer cells into a dormant state that made them harder to kill with standard drugs but more vulnerable to a different form of cell death called ferroptosis. Combining fasting with a ferroptosis-inducing agent eliminated those dormant cells more effectively.22PubMed Central. Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells This is very early-stage work, and nobody should start fasting during cancer treatment without medical supervision, but it illustrates how attacking tumors from multiple metabolic angles simultaneously may overcome resistance that any single approach hits.
Spontaneous Tumor Regression
Rarely, tumors shrink on their own with no treatment at all. Spontaneous regression has been documented across many cancer types, though it remains exceptionally uncommon. Historical case reviews show that regression often follows an acute infection or fever, suggesting the immune system can sometimes mount an effective anticancer response when sufficiently provoked.23PubMed Central. Immunity over inability: The spontaneous regression of cancer Recent work on Merkel cell carcinoma, a skin cancer with a relatively high rate of spontaneous regression, found that the immune response driving spontaneous regression involves the same type of T-cell expansion seen in patients who respond well to immunotherapy drugs.24PubMed Central. Spontaneous tumor regression and immunotherapy response demonstrate clonal T-cell expansion in Merkel cell carcinoma In other words, when the body does manage to shrink a tumor on its own, it appears to be using the same immune machinery that checkpoint inhibitor drugs are designed to unleash. Studying spontaneous regression is difficult precisely because it is so rare, but each documented case offers a window into what successful immune-mediated tumor destruction looks like without any pharmaceutical help.
The Role of the Immune System Across Treatments
One of the most important shifts in thinking about tumor shrinkage over the past two decades is the recognition that almost every treatment has an immune component, not just immunotherapy. When radiation kills tumor cells, the debris those cells release is processed by immune cells called dendritic cells and macrophages, which can then teach the adaptive immune system to recognize the cancer.25PubMed Central. Dying cell clearance and its impact on the outcome of tumor radiotherapy The same happens with chemotherapy and even some targeted drugs. This is why combining these treatments with immunotherapy has become one of the most active areas in oncology: a drug that kills cancer cells directly also primes the immune system, and a checkpoint inhibitor given alongside can amplify that immune priming into a broader, longer-lasting attack. Whether you are looking at a virus engineered to blow up tumor cells from the inside or a fasting regimen that metabolically stresses them, the immune system shows up as a common thread connecting approaches that were originally designed without any immunological intent.